Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD

Key facts

Study ID

NCT01533922

Run by

Boehringer Ingelheim

People needed

295

Starts

2012-03-01

Expected to finish

2013-11-01

Last updated by the study team

2015-09-15

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
• Patients must have relatively stable airway obstruction with a post-bronchodilator FEV1 <80% of predicted normal and a post-bronchodilator FEV1/FVC <70% at Visit 1.
• Male or female patients, between 40 and 75 years of age (inclusive) on day of signing informed consent.
• Patients must be current or ex-smokers with a smoking history of more than 10 pack years.

You may not qualify if…

• Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study
• Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN will be excluded regardless of clinical condition
• Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma.
• Patients with any of the following conditions:
• A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists)
• A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists)
• A history of myocardial infarction within 1 year of screening visit (Visit 1)
• Unstable or life-threatening cardiac arrhythmia
• Hospitalized for heart failure within the past year
• Known active tuberculosis
• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)
• A history of life-threatening pulmonary obstruction
• A history of cystic fibrosis
• Clinically evident bronchiectasis
• A history of significant alcohol or drug abuse
• Any contraindications for exercise testing.
• Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1)
• Patients being treated with any oral ß-adrenergics
• Patients being treated with oral corticosteroid medication at unstable doses
• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program
• Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
• Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit
• Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, BAC, EDTA or any other component of the Respimat® inhalation solution delivery system
• Pregnant or nursing women

Where it is running

• 1237.13.01302 Boehringer Ingelheim Investigational Site — Torrance, California, United States
• 1237.13.01308 Boehringer Ingelheim Investigational Site — Hartford, Connecticut, United States
• 1237.13.01304 Boehringer Ingelheim Investigational Site — Livonia, Michigan, United States
• 1237.13.01307 Boehringer Ingelheim Investigational Site — Pittsburgh, Pennsylvania, United States
• 1237.13.01305 Boehringer Ingelheim Investigational Site — Easley, South Carolina, United States
• 1237.13.01301 Boehringer Ingelheim Investigational Site — Greenville, South Carolina, United States
• 1237.13.01303 Boehringer Ingelheim Investigational Site — Spartanburg, South Carolina, United States
• 1237.13.01306 Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
• 1237.13.54301 Boehringer Ingelheim Investigational Site — Capital Federal, Argentina
• 1237.13.54302 Boehringer Ingelheim Investigational Site — Mar del Plata, Argentina
• 1237.13.61306 Boehringer Ingelheim Investigational Site — Concord, New South Wales, Australia
• 1237.13.61301 Boehringer Ingelheim Investigational Site — Daw Park, South Australia, Australia
• 1237.13.61305 Boehringer Ingelheim Investigational Site — Toorak Gardens, South Australia, Australia
• 1237.13.61304 Boehringer Ingelheim Investigational Site — Footscray, Victoria, Australia
• 1237.13.61302 Boehringer Ingelheim Investigational Site — Prahran, Victoria, Australia
• 1237.13.43303 Boehringer Ingelheim Investigational Site — Linz, Austria
• 1237.13.43301 Boehringer Ingelheim Investigational Site — Thalheim bei Wels, Austria
• 1237.13.32302 Boehringer Ingelheim Investigational Site — Brussels, Belgium
• 1237.13.32303 Boehringer Ingelheim Investigational Site — Edegem, Belgium
• 1237.13.32305 Boehringer Ingelheim Investigational Site — Jambes, Belgium
• 1237.13.32304 Boehringer Ingelheim Investigational Site — Lanaken, Belgium
• 1237.13.32301 Boehringer Ingelheim Investigational Site — Leuven, Belgium
• 1237.13.11302 Boehringer Ingelheim Investigational Site — Hamilton, Ontario, Canada
• 1237.13.11303 Boehringer Ingelheim Investigational Site — Kingston, Ontario, Canada
• 1237.13.11304 Boehringer Ingelheim Investigational Site — Saskatoon, Saskatchewan, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.